CytaCoat and Absorbest announce development and licensing agreement for superabsorbent advanced wound care dressings

This represents CytaCoat’s first commercial deal and involves the co-development of coating capabilities at industrial scale to support the future launch of superabsorbent advanced wound dressings and also dressings for the veterinary market. CytaCoat’s performance enhancing coatings for medical devices target providing multiple product benefits, including improved ease of use, comfort and anti-fouling / anti-biofilm properties to prevent Healthcare Associated Infections (HAI’s).

Prior to confirming the agreement, CytaCoat and Absorbest worked on the evaluation of prototype products featuring enhanced performance characteristics based on CytaCoat’s technologies. Details will be forthcoming once the next development phase and industrial scale up is completed, which is targeted to be during 2025.

Graeme Brookes, CytaCoat CEO, said:
“We are very pleased to have secured this development and licensing agreement with Absorbest, who are focussed specialists in the distinct and important $200 million global superabsorbent dressings market. Through this collaboration we envisage being able to develop a strong commercial business with Absorbest as our partner. Additionally, this collaboration will enable CytaCoat to develop a platform from which to consider further multiple wound care products and collaborations within the $5 billion global advanced wound dressings market.”

Hans Karlsson, Absorbest CEO, said:
“We are looking forward to this cooperation together with the team at CytaCoat, who have a unique solution that works well with our products. The field of infection prevention will have an increased role in the future. Market conditions are also changing now for conventional dressing solutions and this opens up for these types of products with enhanced features. We are excited about this opportunity, which will strengthen our portfolio and improve our total offer on the global market.”

FURTHER INFORMATION:
GRAEME BROOKES, CEO +44 7572425331 graeme.brookes@cytacoat.se

ABOUT CYTACOAT
CytaCoat AB is a Swedish, privately held company stemming out of research from the Karolinska Institute (KI) and the Royal Institute of Technology (KTH). We develop performance enhancing coatings for medical devices, targeting improved ease of use, comfort and anti-fouling / anti-biofilm properties to prevent Healthcare Associated Infections (HAI’s).

Our coatings are based on non-toxic, biocompatible components and have been successfully applied to many materials used in the medical device industry. We are currently conducting clinical investigations with urinary catheters and have also identified advanced wound care as a key focus area for development and commercialisation.
We are targeting multiple routes to market. These include licensing and building the capabilities to produce finished packed sterile product via collaborations with manufacturing partners to support Original Equipment Manufacturer (OEM) sales and sales through distributors. CytaCoat has a strong Swedish investor base, including Segulah Medical Acceleration (SMA).

See www.cytacoat.com

ABOUT ABSORBEST
Absorbest AB is a Swedish development-oriented company, with activities that focus on sustainable, high-performance medical devices. We are acknowledged experts in consumables for advanced wound care and in areas that promote improved hygiene and efficiency in operating theatres. All our products are developed in-house and manufactured under strict control at our production facility. Ultimately, this enables caregivers worldwide to deliver optimised, cost-effective healthcare services.

Our superabsorbent wound dressing product range is available in a range of absorptive capacities, in multiple sizes, for different types of wounds and we are present on all continents and over 40 countries through both direct sales and via distributors. Absorbest has its own subsidiaries in Germany and USA.

See www.absorbest.com